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from remission, progression to long-term adverse outcomes (cirrhosis, decompen-
sated cirrhosis, hepatocellular carcinoma, end-stage liver disease) and commonly 
observed side effects (anemia, neutropenia and rash) along with a gradient of their 
severity. Model inputs were determined from a review of the published literature 
and phase II or III clinical trials. Clinical trials estimates were converted to risk ratios 
to facilitate comparison. Costs were inflated to 2013 US dollars. Costs and quality 
adjusted life years were discounted at standard rate of 5%. Sensitivity analyses 
were performed to assess model sensitivity and address uncertainty. Results: 
Relative to treatment with PR only, response-guided triple therapy with BOC+PR 
was the most cost effective therapy (ICER $28,723/QALY) followed by response-
guided triple therapy with TVR+PR (ICER $64,569/QALY). PR treatments with SIM or 
SOF were dominated by BOC+PR. The model was sensitive to variations in costs of 
initial drug therapy and likelihood of attaining SVR. ConClusions: Addition of 
protease inhibitors to PR therapy improves health outcomes. Response-guided regi-
men BOC+PR was found to be cost-effective for treating newly diagnosed genotype 
1 HCV patients. Shortening of PR therapy guided by a rapid virologic response may 
help reduce overall costs. Robust sensitivity analyses can help in overcoming the 
challenge of sparse data availability.
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Cost-EffECtIvENEss of ErtaPENEm vErsus PIPEraCIllIN/tazobaCtamIN 
IN trEatINg CommuNIty aCquIrEd INtra-abdomINal INfECtIoNs IN 
ColombIa
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1Merck & Co., Whitehouse Station, NJ, USA, 2MSD Colombia, Bogota, Colombia
objeCtives: To compare Ertapenem with piperacillin/tazobactam (pip/tazo) for the 
treatment of moderate to severe community acquired intra-abdominal infections 
(c-IAI) in Colombia health care setting, with respect to cost and outcomes taking 
into account development of anti-microbial resistance (AMR). Methods: A previ-
ously published decision tree model was adapted to estimate cost-effectiveness 
of Ertapenem vs. pip/tazo. Clinical efficacy, adverse events and medical resource 
use were derived from literature. AMR to Ertapenem and pip/tazo was calculated 
as weighted average based on the % distribution of different pathogens in c-IAI in 
Colombia and the sensitivity of Erta vs. pip/tazo for each pathogen from Colombia 
SMART data. The resistance-adjusted effectiveness is then computed based on effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall resistance of Ertapenem vs. pip/tazo for c-IAI is 21.4% 
vs. 43.4%. The resistance-adjusted effectiveness are 70.3% vs. 46% for Ertapenem vs. 
pip/tazo. Daily drug costs are 133,550 (Ertapenem) vs. 34,989 (pip/tazo) Colombian 
Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line treatment 
& cost of AEs) are 7,162,081 (Ertapenem) vs. 7,230,902 (pip/tazo) Pesos. During the 
first hospitalization period, Ertapenem is associated with a 24.3% higher treatment 
success rate, and a 68,821 Pesos in cost saving when compared with Pip/tazo. The 
Incremental cost per successfully treated patient (ICER) is -283,405 Colombian Pesos 
($145.39 USD) for Ertapenem vs. Pip/tazo. ConClusions: Accounting for local anti-
microbial resistance, Ertapenem is more effective and cost-saving vs. pip/tazo for 
the treatment of moderate to severe community acquired intra-abdominal infec-
tions in Colombia.
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Cost-EffECtIvENEss aNalysIs of JoINt vaCCINatIoN WIth 13-valENt 
PNEumoCoCCal CoNJugatE vaCCINE (PCv13) aNd INfluENza vaCCINE IN 
taIWaN durINg sEasoNal INfluENza
Wu D.B.C., Chong H.Y., Lee K.K.C.
Monash University Malaysia, Kuala Lumpur, Malaysia
objeCtives: Pneumococcal diseases and influenza have caused substantial clini-
cal and economic burden in Taiwan especially in high-risk groups such as infants 
and elderly. It has been shown that influenza can increase the risk of pneumococ-
cal diseases compared to those uninfected during a seasonal influenza. The cost-
effectiveness of PCV13 has been previously established. Influenza vaccine (INFv) is 
generally considered as an effective prevention of influenza and is therefore useful 
in alleviating the burden of influenza in reducing morbidities and mortalities. This 
study aims to evaluate the potential cost-effectiveness of joint 13-valent pneumo-
coccal conjugate vaccine (PCV13) and INFv vs influenza vaccine alone for infants and 
elderly. Methods: An age-stratified decision tree model was developed to simulate 
clinical and economic impacts of joint vaccination with PCV13 and INFv in newborns 
and elderly compared to influenza vaccine alone during a seasonal influenza over a 
1-year time horizon. Direct medical costs, epidemiological, demographic parameters 
are Taiwan-specific. Effectiveness of vaccines is based on previous trials adjusted for 
local age-specific stereotype distributions. Herd effect estimates were extrapolated 
from the US post-PCV surveillance data. The study was performed from a payer 
perspective. Current market prices of vaccines were used. One-way and multivari-
ate probabilistic sensitivity analyses were performed to identify influential factors 
to outcomes. Results: Compared to influenza vaccination alone, over 1-year time 
horizon, joint vaccination of PCV13 and INFv is predicted to prevent 386 cases of 
invasive pulmonary diseases, 4,232 cases of all-cause pneumonia, 32,652 cases of 
acute otitis media and 202 deaths (equivalent to 3,131 life years). The universal 
vaccination is expected to save NT$352,593,433 (US$11,753,114) in direct medical 
cost equivalent to NT$947,629 (US$31,587) per life year gained. The results are sen-
sitive to vaccine prices and incidence of influenza. ConClusions: Using WHO-
recommended cost-effectiveness threshold, universal vaccination program with 
PCV13 and INFv appears to be a cost-effective policy in Taiwan.
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Cost-EffECtIvENEss of varIous ClostrIdIum dIffICIlE INfECtIoN (CdI) 
trEatmENts IN PatIENts WIth rECurrENt INfECtIoNs
Massachi S., Hay J.W.
University of Southern California, Los Angeles, CA, USA
group (65%). After 6 months, patients treated with SISEM had substantially higher 
ulcer-free weeks compared to SC (20.0 versus 16.8, respectively). Expected direct 
costs per patient were $2,360 for SISEM and $1,326 for SC. The incremental cost-
effectiveness ratio (ICER) for SISEM was $349 (approximately $50/day), indicating 
that for each $349 paid for SISEM therapy patients gained one additional ulcer-free 
week. ConClusions: SISEM yielded better outcomes at a slightly higher cost in 
patients with mixed A/V and VLUs. SISEM is an effective treatment for wound heal-
ing and should be considered for use in the management of mixed A/V and VLUs.
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objeCtives: To assess the cost-effectiveness of the introduction of the quadriva-
lent HPV vaccine in Argentina. Methods: Using a transmission dynamic model 
developed and published by Elbasha in 2008 we evaluated the routine vaccination 
of 11-year-old girls over a time horizon of 100 years from the perspective of the 
health care system Results: The model showed that the introduction of the vac-
cine will gradually reduce the incidence of cervical cancer, CIN 1/2/3, and genital 
warts related to HPV 6/11/16/18. When compared with non-vaccination, a women 
who completed the three dose scheme will experience a reduction of cervical cancer 
incidence and death, CIN2/3, CIN1 and genital warts of 58,6%, 59,2%, 56,7%, 56,3% 
and 67,3% respectively. Considering a 5% discount rate and a 43,8% of complete 
scheme coverage without heard immunity, the incremental cost-effectiveness ratio 
(ICER) was 795 USD per quality-adjusted life-year (QALY) gained. The additional 
protection against HPV types 6/11 has a great influence in the cost-effectiveness, 
the ICER was almost doubled when not contemplated the protection against HPV 
6/11. The most influential parameters on the scenario analysis were the discount 
rate, the cost of the vaccine and the cost of treatment. However, the vaccine was 
very cost-effective (less than one gross domestic product= 7844 USD) in all the tested 
scenarios. ConClusions: The implementation of routine HPV vaccination with 
the quadrivalent vaccine in 11-year-old girls in Argentina could provide significant 
benefits to public health by reducing cervical cancer incidence and death rates 
and the incidence of CIN 1/2/3 and genital warts, making it a highly cost-effective 
intervention
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assEssmENt of rEal-lIfE PrEdICtIvE PoWEr of a NEW Cost-
EffECtIvENEss modEl IN hIv: aNtIrEtrovIral aNalysIs by moNtE Carlo 
INdIvIdual sImulatIoN (aramIs-dtg)
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objeCtives: The validation of complex economic models against observational 
cohorts tests the accuracy of structural assumptions in models and the relation-
ship between variables and the validity of model outcomes. However, these exer-
cises are seldom conducted and published. The study objectives were to assess 
how well a newly developed economic model for HIV (ARAMIS-DTG) predicts CD4+ 
cell-count changes and AIDS-related outcomes and to explore drivers of eventual 
discrepancies between simulated and observed outcomes. Methods: Clinical out-
comes from ARAMIS-DTG were compared to an observational cohort of patients 
initiating antiretroviral treatment in the British Columbia Centre for Excellence 
(BC-CfE) between 2008 and 2011. Baseline population characteristics and treat-
ment efficacy were modified to reflect the observational cohort in the model, and 
mean changes in CD4+ cell-count and incidence rates of AIDS-related events were 
simulated in ARAMIS-DTG. The impact of relevant ARAMIS parameters on these 
outcomes, such as mortality or virological suppression, was assessed in sensitivity 
analyses. Results: In the base case analysis, the average CD4+ cell-count over five 
years increased from 295 to 682 cells/µL in ARAMIS-DTG and from 303 to 532 cells/
µL in the BC-CfE cohort, reflecting a potential overestimation of adherence in the 
clinical trial setting. However, despite a higher CD4+ cell-count, the incidence of 
AIDS-related events was also higher in ARAMIS: 3.81 vs. 2.84 per 100,000 person-
years, suggesting the higher incidence of AIDS-related events in ARAMIS-DTG was 
mostly attributable to the pre-2005 rates used to inform the model. Sensitivity analy-
ses produced similar results without adjusting ARAMIS-DTG to the BC-CfE cohort 
characteristics. ConClusions: Although results highlight the need for calibrating 
economic models and accounting for factors such as adherence to achieve better 
alignment with real life data, in the particular case of ARAMIS-DTG the differences 
between simulated and observed outcomes did not significantly affect its overall 
cost-effectiveness outcomes.
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Cost-EffECtIvENEss of PharmaCothEraPIEs for trEatmENt NaïvE 
hEPatItIs C gENotyPE 1 PatIENts: a PayEr’s PErsPECtIvE
Jalundhwala YJ, Manzoor B.S., Patel H., Cheng W.H., Patel P., Touchette D.R.
University of Illinois at Chicago, Chicago, IL, USA
objeCtives: Our objective was to evaluate the cost-effectiveness of currently 
recommended pharmacotherapies [response-guided triple therapies with 
pegylated-interferon plus ribavarin (PR) plus boceprevir (BOC) or telaprevir (TVR) or 
simeprevir (SIM) or sofosbuvir (SOF)] for the treatment of newly diagnosed patients 
with genotype 1 chronic hepatitis C virus (HCV) infection, from payer’s perspec-
tive. Methods: A Markov cohort model was developed to simulate the disease 
progression of treatment naïve HCV patients initiating therapy. The model included 
the following outcomes: sustained virologic response (SVR) i.e. absence of detect-
able RNA of virus in blood serum at 12/24 weeks after ending treatment, relapse 
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objeCtives: Artemisinin combination based therapy (ACT) was started in Ghana in 
2002 as a result of failure of monotherapy in the treatment of falciparum malaria. 
The decision to change was in line with recommendations from the World Health 
Organisation. ArtesunateAmodiaquine (A-Q) is the preferred combination drug of 
choice for the treatment of uncomplicated malaria and Artemether-Lumefantrine 
(A-L) is an alternative first line option. This study evaluates the cost-effectiveness 
of A-Q compared with A-L among under-five year olds in Ghana. Methods: In 
this study a decision analytic model using a decision tree was developed to assess 
the cost-effectiveness of the two treatments. Cost of illness and cost of medication 
(Coartem paediatric and Camoquine plus) were determined using figures from the 
National Health Insurance Scheme (NHIS) Ghana and from wholesalers respectively. 
Transportation cost was estimated using exit interviews. With the help of rand-
omized controlled trials we estimated malaria cases averted (using clinical failure 
rates) over a 28 day period post treatment with each drug. Costs were discounted 
by 3% over a five year period but malaria cases averted 28 days after treatment 
was not discounted. Incremental costs per uncomplicated malaria case averted 
was then determined. Results: The cost of illness per episode of uncomplicated 
malaria was 7.50 Ghana cedis (bundled NHIS cost) and transportation cost was 3.00 
Ghana cedis. The incremental cost effectiveness ratio of artesunate-amodiaquine 
compared with artemether-lumefantrine was 16 Ghana cedis per uncomplicated 
malaria case averted. ConClusions: This economic evaluation showed that in the 
Ghanaian setting, treating uncomplicated malaria in under-five year old children 
with artesunate-amodiaquine was more cost-effective compared with artemether-
lumefantrine.
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Cost-EffECtIvENEss of sINglE vErsus multIPlE tablEt rEgImENs for 
trEatmENt of hIv-1 INfECtIoN
Sweet D.E.1, Zhuo D.Y.2, Macalalad A.R.2, Signorovitch J.2
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objeCtives: Favorable clinical outcomes in HIV-1 infection require optimal 
adherence to multi-drug antiretroviral (ARV) regimens. Single-tablet regimens 
(STRs) simplify treatment compared with multiple-tablet regimens (MTRs) and are 
associated with improved adherence, improved virologic outcomes and reduced 
hospitalizations. To date, models assessing the economic value of STRs have been 
based only on clinical trial evidence from idealized settings with close follow-up. 
Economic models have not yet incorporated real-world evidence comparing adher-
ence and effectiveness between STRs and MTRs. Methods: A patient-level simu-
lation model was used to compare health and economic outcomes between STRs 
and MTRs in the US. STRs included EVG/COBI/FTC/TDF, EFV/FTC/TDF and RPV/FTC/
TDF. MTRs included a 3rd agent plus 3TC+TDF backbone. Before incorporating real-
world evidence, the model was validated against published economic projections 
based on clinical trial results. Real-world evidence identified via systematic litera-
ture review was then incorporated for differences in adherence, resistance, and 
hospitalization risk between STRs and MTRs. Upcoming generic drug scenarios 
included 25-75% cost reductions and lower average drug costs for MTRs vs. STRs 
by $1,300 to $6,100 per year. All costs were inflated to 2013 USD. Results: After 
incorporating real-world evidence, the virologic suppression rates at 24 weeks 
were 72.7% and 63.2% for STRs and MTRs, respectively. When initiating with STRs 
vs. MTRs, short-term inpatient costs (at 2 years) were reduced by 29% ($7,660 vs. 
$10,819) and an additional 2 life years (20.6 vs. 18.6) were gained. The discounted 
life-time incremental cost-effectiveness ratios ranged from ~$26,000 to $52,000 
per QALY, depending on assumed generic discounts. ConClusions: STRs have 
demonstrated superior clinical and economic outcomes compared to MTRs in 
real-world settings. Incorporating this evidence into a cost-effectiveness model 
illustrated that initiation with STRs is a cost-effective strategy compared with 
initiation with MTRs, due to greater real-world adherence and effectiveness, and 
reduced inpatient costs.
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objeCtives: In the United States, chronic hepatitis C (HCV) is responsible for more 
death and disease than HIV/AIDS. It is the most common chronic blood-borne infec-
tion, and remains a major cause of death and illness in the United States. Current 
standard of care treatments for HCV have difficult dosing regimens and are often 
accompanied by undesirable side effects. With a host of new clinically promis-
ing, interferon-free, combo therapies currently in clinical trials it is important to 
assess the cost-effectiveness of the current and future treatment options for chronic 
hepatitis C. The objective of the current study is to assess the cost-effectiveness 
of current, and future, treatment options for treatment naïve genotype 1 chronic 
hepatitis c patients. Methods: Cost-effectiveness analysis using a Markov model 
of the natural disease progression of HCV infection and impact of treatment. We 
use a simulated 20 year model of a hypothetical cohort of 1000 treatment naïve 
genotype 1 HCV patients to assess the cost-effectiveness of no treatment, boceprevir 
+ pegylated interferon + ribavirin (BOC+P+R), telaprevir + pegylated interferon + 
ribavirin (TVR+P+R), and sofosbuvir + ledipasvir + ribavirin (SOF+LVR+R). Results: 
Over the 20 year time horizon of this cohort no treatment would result in 9.76 QALYs 
and a total discounted cost of $41,434, while BOC+P+R resulted in 11.06 and $132,070, 
TVR+P+R in 11.08 and $132,482, and SOF+LVR+R in 11.90 and $172,384, respectively. 
Our analysis showed that BOC+P+R and TVR+P+R were weakly dominated, while 
SOF+LVR+R was the most cost-effective therapy. ConClusions: The interferon-free 
combo therapy SOF+LVR+R is the most cost-effective treatment option, with an ICER 
of $61,291 when compared to no treatment. These results have important economic, 
and policy implications for the treatment of chronic hepatitis C.
objeCtives: The purpose of this cost-effectiveness model is to compare the cost-
effectiveness of metronidazole, oral vancomycin, fidaxomicin, and fecal transplants 
for CDI. Methods: This is a cost-effectiveness model from the societal perspective 
using probabilities, cost, and utility parameters from scientific literature. A deci-
sion tree model for mild/moderate CDI compares metronidazole, oral vancomycin, 
fidaxomicin, and fecal transplant. A decision tree for severe CDI compares oral 
vancomycin, fidaxomicin, and fecal transplant. Both decision trees capture up to two 
recurrences and/or the necessity of a colectomy. Both models account for short-term 
and long-term costs of CDI. One-way sensitivity and threshold sensitivity analy-
sis were used to assess the robustness of the data. Results: For mild-moderate 
CDI, fecal transplant is a dominant treatment option, as it reduces costs to $13,537 
and increases effect to 11.85 QALYs. The best alternative to fecal transplants in 
mild-moderate disease is fidaxomicin if WTP/QALY > $0. For severe disease, fecal 
transplant is still a dominant treatment option, as it reduces costs to $13,537 and 
increases effect to 11.84 QALYs. The best alternative to fecal transplants in severe 
CDI is oral vancomycin at all WTP/QALY. For mild-moderate disease indicated that 
fecal transplants are favored to fidaxomicin as long as the cost of fecal transplants 
< $4,515, fecal transplant cure rate > 0.883, fecal transplant recurrence rate < 0.185, 
fidaxomicin cure rate < 0.955, and fidaxomicin recurrence rate > 0.02. For severe 
disease indicated that fecal transplants are favored to oral vancomycin as long as 
the cost of fecal transplants < $4,860, fecal transplant cure rate > 0.79, and the fecal 
transplant recurrence rate < 0.36. ConClusions: In both the treatment of mild/
moderate and severe CDI, it is cost-effective to use fecal transplants as standard 
protocol rather than the last resort.
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Cost-EffECtIvENEss of ErtaPENEm vErsus CEftrIaxoNE IN trEatINg 
urINary traCt INfECtIoNs IN ColombIa
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objeCtives: To compare Ertapenem with ceftriaxone for the treatment of uri-
nary tract infections (UTI) in Colombia health care setting, with respect to cost 
and outcomes taking into account development of anti-microbial resistance 
(AMR). Methods: A previously published decision tree model was adapted to 
estimate cost-effectiveness of Ertapenem vs. Ceftriaxone in the treatment of UTI. 
Clinical efficacy, adverse events and medical resource use were derived from lit-
erature. AMR to Ertapenem and ceftriaxone was calculated as weighted average 
based on the % distribution of different pathogens in UTI in Colombia and the 
sensitivity of Ertapenem and Ceftriaxone to each pathogen from Colombia SMART 
data. The resistance-adjusted effectiveness is then computed based on the effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall AMR of Ertapenem vs. Ceftriaxone for UTI is 7% 
vs. 30%. The resistance-adjusted effectiveness is 83% vs. 64% for Ertapenem vs. 
Ceftriaxone. Daily drug costs for Ertapenem vs. Ceftriaxone are 133,550 vs. 8,550 
Colombian Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line 
treatment & cost of AEs) are 446,871 vs. 188,268 Pesos. During the first hospitaliza-
tion period, Ertapenem is associated with a 18.8% higher treatment success rate, 
and 178,377 Pesos more in total cost when compared with Ceftriaxone. The incre-
mental cost per successfully treated patient (ICER) is 9,488 Pesos ($4.87 USD) for 
Ertapenem vs. Ceftriaxone. ConClusions: Accounting for local anti-microbial 
resistance, Ertapenem is more effective as well cost-effective vs. Ceftriaxone for 
the treatment of urinary tract infections in Colombia.
PIN52
Cost-EffECtIvENEss of oNCE daIly dolutEgravIr vErsus tWICE daIly 
raltEgravIr as fIrst-lINE aNtIrEtrovIral thEraPy IN hIv-INfECtEd 
adults IN thE uNItEd statEs
Keeling N., Crumby A., Nunna S.
University of Mississippi, Oxford, MS, USA
objeCtives: Dolutegravir is a new FDA-approved (August 2013) antiretroviral medi-
cation in the integrase inhibitor class which could be a possible first-line agent for 
treatment of antiretroviral naïve HIV infected adults. A phase III trial (SPRING-2) 
compared clinical efficacy of dolutegravir versus raltegravir, a currently recom-
mended first-line agent, and demonstrated non-inferior viral response rates at 96 
weeks for dolutegravir (81%) when compared to raltegravir (76%). This study aims to 
estimate the costs and effectiveness of dolutegravir and raltegravir and to determine 
the cost-effectiveness of dolutegravir versus raltegravir. Methods: A decision anal-
ysis model was constructed to determine the cost-effectiveness of treatment with 
dolutegravir versus treatment with raltegravir as a first-line agent from the perspec-
tive of the provider. First-line efficacy data was derived from the previously-men-
tioned published phase-III trial (SPRING-2). Drug costs were estimated using average 
whole sale price and data were obtained using the Red Book. Costs associated with 
second-line treatment as well as adverse effect treatment were also derived from 
the Red Book. The model was run over a period of 192 weeks using TreeAge Pro 
2013. Results: The estimated costs for the dolutegravir arm and raltegravir arm 
at 192 weeks were $100,750.28 and $96,622.17, respectively. The incremental cost-
effectiveness ratio for dolutegravir versus raltegravir was estimated to be $412,811 
per 1% increase in virological success. Sensitivity analysis performed on the cost 
parameters confirmed the primary cost effectiveness results. ConClusions: The 
analysis provided cost-effectiveness findings of dolutegravir versus raltegravir for 
HIV-infected treatment naïve patients and showed favorable cost-effectiveness 
results for raltegravir when using a 192 week time frame.
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Cost-EffECtIvENEss aNalysIs of artEsuNatE-amodIaquINE vErsus 
artEmEthEr-lumEfaNtrINE for thE trEatmENt of uNComPlICatEd 
malarIa IN uNdEr-fIvE yEar old PatIENts IN ghaNa
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